bluuebunny/crossref_metadata_2025_split huggingface dataset:
FC03-07 - Future Strategies for Vocational Rehabilitation in Schizophrenia
Authors: Urbanek C. , Neumann K. , Schoenhoff M. , Dettling M. 
Published: June 2010

IntroductionSocial implications and long-term consequences of mental disorders regarding sick days at work, unemployment rates and early retirement are substantial. There is no clear understanding 1)whether and which social psychiatric strategies of vocational rehabilitation and2)whether and how atypical antipsychotics are successful in supporting vocational rehabilitation in schizophrenia.ObjectivesPrimary objective was to demonstrate the enhanced ability of schizophrenic patients to be successfully in employment after attending specific “job-consulting” programs. Secondary objective was to demonstrate positive effects of ziprasidone and risperidone on work-related functions.AimsAim of the study was to enlighten the complex relationship between working performance of schizophrenic patients, their social psychiatric and medical treatment, and their cognitive capabilities in a first step.MethodsThe study was conducted in inpatients, day-clinic- or outpatients diagnosed with schizophrenia, paranoid type (ICD 10: F20.0). All patients received regular pharmacological treatment and intense cognitive training, additionally one group completed specific “job-consulting” programs. ANT, CPT, WCST, PANSS and WBN were performed after 3, 6, 12 and 24 months.ResultsAt present eighteen schizophrenic patients (6 female and 12 male, mean age: 33.6 years) have been included in the study. Analyzing the data after 3 months the results are:1)specific “job-consulting” programs increase the probability of employment2)both, ziprasidone and risperidone, exert positive and comparable effects in work-related functions,3)the better the cognitive capability the better the vocational outcome.ConclusionsSpecific “job-consulting” programs constitute a clinically relevant therapeutic option in vocational rehabilitation of schizophrenic patients.
FC04-01 - Fast (Fight Against Stigma): Promoting Mental Health Through an Original Public Private Partnership (PPP)
Authors: Moussaoui D. , Gerard D. 
Published: June 2010

RationaleAlthough mental disorders are a major contributor to the Global Burden of Diseases, in many low- and lower-middle-income countries, mental health care is still accessible to only a minority.Psychiatric disorders haven’t benefited from dramatic progresses seen in other fields as pandemic diseases.ObjectiveTo increase equity in access to care for psychotic patients in low- and lower-middle -income countries.MethodThrough mental health facilities at the primary care level, availability of psychosocial support, accessibility of medicines, awareness and reduced stigma, the program addresses what is seen as the main barriers to access to care. To achieve this objective, institutional partners (Ministries of Health), a worldwide NGO (World Association for Social Psychiatry), and a leader of the pharmaceutical industry (sanofi-aventis) are associated through PPPs. The complementary expertise and resources of the partners are pooled to build-up the existing health infrastructures and increase efficacy in patient care.ResultsIn partnership with local psychiatric networks, pilot projects have been launched in Morocco and Mauritania, and others are in preparation (such as Armenia and Guatemala).The programs combine actions dedicated to:•Advocacy efforts towards political and administrative decision makers;•Increase awareness of communities of mental health issues;•Psycho-educate patients and families;•Encourage the creation of associations of patients’ families;•Train health care professionals;•Organize a sustainable supply of high quality antipsychotics.ConclusionThe FAST project encourages the collaboration of all partners. It could be an example of innovative ways to address mental health challenges in developing countries.
YSFC01-01 - Neural Correlates of Verbal Working Memory Dysfunction in Early-Onset Schizophrenia: a Functional Magnetic Resonance Imaging Study
Authors: Kyriakopoulos M. , Dima D. , Kempton M. , Hadjulis M. , Frangou S. 
Published: June 2010

ObjectivesWorking memory (WM) deficits are among the core cognitive abnormalities in schizophrenia. WM is subserved by widely distributed fronto-parietal networks and is undergoing robust development during adolescence. Studying the neural correlates of WM dysfunction in early-onset schizophrenia (EOS) will advance our understanding of aberrant neurodevelopmental processes in the disorder.MethodNineteen patients with EOS aged 13-19 and 20 matched healthy participants underwent functional Magnetic Resonance Imaging (fMRI) as they performed a N-back verbal WM task with 3 levels of difficulty (1-back, 2-back, 3-back). Following matching for task performance, 14 patients were compared to 20 controls, using non-parametric whole brain and region of interest approaches followed by psycho-physiological interaction analysis (PPI) with seed voxel from the left parietal cluster.ResultsRegions within the left prefrontal cortex, the left insula and bilateral anterior cingulate cortex showed reduced activation in EOS patients compared to healthy participants at the 2-back condition. In addition, ROI analysis at the same condition revealed hypoactivation in the EOS group with large effect sizes for left prefrontal and parietal regions. The PPI results revealed negative functional connectivity in the healthy participants’ group but not in EOS between left parietal and right parietal and bilateral frontal regions.ConclusionsOur results support compromised function within the left prefrontal-cingulate network and left insula during the N-Back verbal WM task in patients with EOS compared to healthy participants. They also indicate the possibility of more widespread fronto-parietal network dysfunction, most noted in the left hemisphere in the disorder.
CS05-03 - Human sexuality: New Developments in Neurobiology, Diagnosis and Treatment
Authors: Balon R. 
Published: June 2010

Mainstream psychiatry has shown only a sporadic interest in the understanding and treatment of sexual disorders. This lack of interest is puzzling, especially at the time of new developments in the study of human sexuality and the emergence of a new interdisciplinary field of sexual medicine.Human sexuality encompasses various areas related to contemporary psychiatry, such as quality of life, quality of relationship, sexual side effects of psychotropic medications, and the association of sexual dysfunction with various mental and physical illnesses, including substance abuse. Sexual dysfunction, with its complex regulation involving the central and the peripheral nervous systems, hormones, psychological, cultural, psychosocial and developmental factors actually seems to be a primary target for psychosomatic medicine and psychiatry. As noted, “Sexuality is the ultimate unity of body and mind.”This lecture will review the recent developments in the area of human sexuality, including diagnostic considerations in the context of proposed revisions of the existing diagnostic systems, neurobiology, imaging, psychology and psychopharmacology; and will also focus on combining the new findings into an integrated model of management of sexual dysfunctions.
P01-02 - Depression and obstructive sleep apnea - results from a 12-month survey in routine clinical practice
Authors: Acker J. , Piehl A. , Herold J. , Scholz F. , Ficker J. , Niklewski G. , Richter K. 
Published: June 2010

ObjectivesPatients with untreated obstructive sleep apnea often report depressive symptoms, such as low mood, loss of interest and reduction of drive. In this study we examined the frequency of significant depressive symptoms amongst patients with untreated obstructive sleep apnea over a one year period.MethodsFrom January to December 2008 we screened 1260 consecutive patients with untreated obstructive sleep apnea (AHI > 9) seen at our Center for Sleep Medicine were screened for depression. Based on self-administered questionnaires, patients with significant depressive symptoms were defined as having either a BDI II score ≥ 14 or WHO-5 ≤ 13. Additionally, severity of depression was rated based on BDI II scores.ResultsDepressive symptoms were reported frequently. Based on BDI-II, 27.9% of patients report significant depressive symptoms. Of these, 46.2% were mild, 35.9% moderate and 17.9% severe. In addition, 52.6% of patients self-reported feeling unwell based on their WHO-5 scores.ConclusionsSignificant depressive symptoms measured by standardised self-rating scales were detected in over a quarter of our patients with untreated sleep apnea. It remains unknown whether treatment of OSA alone abolishes depressive symptoms, or whether depressive mood may reduce the compliance with treatment. Patients may need an interdisciplinary approach to initial treatment.
P01-04 - A Descriptive Study of Patients with Bipolar Affective Disorder Admitted in Brief Hospitalization Unit, University Hospital of la Princesa
Authors: Albillo J.D. , Eaton K. , Lázaro M. , Peregrin E. , Perez B. , Ruberte A. , Betancor D. , Collazos R. , Nieto M. , Martín de Francisco L. 
Published: June 2010

IntroductionPatients with Bipolar Affective Disorder have high rates of somatic comorbidity and it's necessary to know the characteristics of these patients to develop preventive and therapeutic strategies.ObjectivesTo describe twelve patients diagnosed with BAD admitted to a Brief Hospitalization Unit.MethodsEvaluation by a questionnaire which recorded sociodemographic data (sex, age, marital status, education, occupation, employment status); medical management indicators (average stay, number of previous admissions and if re-entering during the study); previous treatments (antipsychotics, antidepressants and benzodiazepines); somatic background (presence of cardiovascular risk factors that contrasted with taking blood pressure, BMI calculation, ECG and complete analytical) and consumption of toxic substances.Results58.33% are women with a mean age of 41.91 years and 58.33% in single cases. 58.33% has secondary education, although the 41.66% isn’t working.The average stay of admission is 20.83 days. 50% had between 1 and 4 more admissions and 33.33% re-enters.25% doesn’t take medications. Of the rest, 77.77% taking neuroleptics, being the most common option with 57.14% treatment with quetiapine. The 88.88% takes mood-stabilizing and the 44.44% benzodiazepines.No patient has altered the glucose profile. The 8.33% has high blood pressure control and 25% altered lipid profile. The average BMI is 28.64The 66.66% smoke. The 33.33% consumed alcohol and cannabis on 16.66%.ConclusionsPatients with BAD have high proportions of cardiovascular risk factors and important consumption of toxic substances. Reflected the impact of the disease in the sociolabour field and the need for many hospital admissions because of the chronic course and poor therapeutic adherence.
P01-101 - Unique: Assessing the Efficacy of Quetiapine Fumarate Augmentation of SSRI or SNRI Treatment in SSRI- or SNRI-resistant Major Depressive Disorder
Authors: Lejeune J. , Taeter C. , Duquenne V. , Goodman N. 
Published: June 2010

ObjectivesThe UNIQUE study assessed the effect of Quetiapine fumarate augmentation on the overall depression status of patients with major depressive disorder and who did not respond to any acute treatment with selective serotonin reuptake inhibitors (SSRIs) or selective noradrenalin reuptake inhibitors (SNRIs) and naïve to any atypical antipsychotics.MethodsBetween March 2006 and November 2007, 39 male and female patients, aged 18-65, were enrolled into this four-week, open label, non-comparative, multicentric, phase II prospective study. Treatment with Quetiapine fumarate began at enrolment, with a titration to a target dose of 300mg. The following scales were completed during all five visits: Montgomery-Asberg Depression Rating Scale (MADRS); Clinical Global Impression (CGI); Brief Psychiatric Rating Scale (BPRS); Sheehan Disability Scale (SDS).ResultsAll questionnaire mean scales were significantly reduced (Friedman P< 0.0001) at the end of the study from baseline: MADRS 16.9 (12.8-21.0); CGI 1.94 (1.52-2.37); BPRS 10.3 (6.7-13.6); SDS 8.5 (5.6-11.5). Response, defined as a reduction in MADRS total score >50% was observed in 45.9% of the 37 patients completing at least 2 weeks of the study and 37.8% were considered in remission e.g. MADRS total score ≤ 12 at visit 5.ConclusionsQuetiapine fumarate augmentation improved the overall depression status of patients resistant to SSRI or SNRI treatment.
P01-102 - Mania as a First Symptom of Wilson's Disease: a Case Report
Authors: Tatay A. , Lloret M. , Merino T. , Harto M.A. 
Published: June 2010

IntroductionProgressive hepatolenticular degeneration or Wilson's disease is a rare autosomal recessive genetic disorder of copper metabolism, which is characterised of hepatic and neurological disorders due to the accumulation of copper in organs such as the liver or the basal ganglia. The manifestations of Wilson's disease are multiple and sometimes insidious, which makes the diagnosis very complicated.Objective and methodA clinical case was followed and reviewed to illustrate the psychiatric symptoms in Wilson's disease.ResultsA 23-year-old male came to the emergency room presenting insomnia, logorrhea, euphoria, irritability and a slight tremor in the upper limbs. Symptoms started two weeks before. The previous year, he was diagnosed of bipolar disorder after a manic episode which required inpatient treatment with risperidone and lithium. During the actual hospitalization, the tremor increased progressively and affected all four limbs and his head. He was then examined by neurology and an ophthalmology service, who ordered some specific complementary exams. Low levels of ceruloplasmin and serum copper and high levels of urinary copper confirmed the diagnosis of Wilson's disease. Treatment with copper chelants was introduced and the psychiatric symptoms and the analyses got better in several weeks.ConclusionsEven a typical presentation of a psychiatric syndrome can be part of the spectrum of an organic illness. So an organic etiology should always be considered in the differential diagnosis, as sometimes it is possible to be treated.
P01-105 - Characteristics and One-year Outcome of Untreated Anxiety and Depression
Authors: van Beljouw I.M.J. , Verhaak P.F.M. 
Published: June 2010

ObjectiveTo study reasons for not receiving treatment, and examine characteristics and one-year outcome of untreated anxiety and depression.MethodsData were used of 743 primary care patients with a six-month anxiety or depressive disorder in the Netherlands Study of Anxiety and Depression (NESDA). Diagnoses were confirmed by the Composite Interview Diagnostic Instrument (CIDI). Patients’ perceived need for care, service utilisation, and reasons for no treatment were assessed by the Perceived Need for Care Questionnaire (PNCQ).Results43% of the respondents received no treatment. Of these untreated patients, 25% did not perceive a mental problem; 26% perceived no need for care; and 49% expressed a need for care which was not met. Untreated patients with a treatment need showed the same symptom severity and disability as treated patients, and reported even more loneliness. Compared to other untreated patients, they were more handicapped regarding clinical and psychosocial functioning.After one year, treated and untreated patients with a treatment need showed a poorer outcome than untreated patients without a self-perceived mental problem or need for care.ConclusionsMany patients with anxiety or depression do not seek treatment. Half of them are probably right: they do not perceive a mental problem or treatment need, suffer from relatively mild symptoms, and show a favourable one-year course. Untreated patients with a perceived treatment need, however, suffer from severer symptoms, and show a poorer outcome than other untreated patients. Therefore, care providers should pay considerable attention to this worrisome group.
P01-107 - Effects of Pre-sleep Negative Mood on Subsequent Sleep
Authors: Vandekerckhove M. , Houthuys J. , Weiss R. , De Valck E. , Cluydts R. , Berckmans D. , Haeck B. , Verbraecken J. 
Published: June 2010

ObjectivesUntreated disrupted sleep is an important precursor for the development of depression. Several studies have confirmed the negative impact of pre-sleep cognitive and emotional activity such as worry and negative affect on subsequent sleep. Emotional stress may affect latencies to sleep onset, to REM-sleep and other markers of sleep disruption such as arousals. The way we cope with emotional stressors and events may have important effects on subsequent sleep.MethodsIn this study we investigated the effects of a failure-experience on polysomnographically recorded sleep in volunteers. Furthermore we explored whether dispositional coping factors such as emotion regulation moderate this effect.ResultsIn contrast to the control condition the effect of the failure induction was clearly observed in emotional experience as well as within the physiological sleep architecture. Furthermore, we notice a tendency in which not only emotional experience, but also sleep physiology was affected by low and high emotional approach as emotion regulation style (cf. Stanton, 2000).ConclusionsThe present study has shown that emotional stress as a failure experience before sleep-goes together with a worsening of mood, an increase of level of rumination and enhanced sleep fragmentation with a moderating effect of emotion regulation as dispositional factor.
P01-108 - The Influence of the Conflicting Paradigms over the Prognosis in Major Depressive Disorder
Authors: Vasile D. , Vasiliu O. , Vasile M.L. , Mangalagiu A.G. , Badescu E. , Petrescu B.M. , Bogdan V. , Ojog D.G. 
Published: June 2010

ObjectiveTo evaluate the impact of conflicting patient and psychiatrist conceptualizations of the depression over the treatment response and general prognosis.MethodsA group of 25 patients, mean age 36.8, diagnosed with major depressive disorder, first depressive episode, according to DSM IV TR criteria, have completed a closed-ended questionnaire that included their perspective over the depression (on a 7 points Likert scale, from the pure medical/pharmacological, to the pure psychological/reactive paradigm). Psychiatrists who managed their treatment responded to a similar questionnaire regarding their preferred method of treatment. Patients were evaluated initially and after 3 and 6 months using Hamilton Depression Rating Scale-17 items (HAMD), Beck Depression Inventory (BDI), Global Assessment of Functioning. Patients satisfaction over the treatment (on a 10 points visual analogic scale) was evaluated at endpoint.ResultsPatients who received a treatment corresponding to their preferred paradigm (n=17) responded better (−5.6 on HAMD, −4.5 on BDI, +7.6 on GAF, p< 0.01) to the treatment, compared to the group where the paradigms weren’t the same. The satisfaction over the treatment was also significant higher in the first group (+2.5, p< 0.01). Patients who have discussed their beliefs about the disorder and were informed by their psychiatrists about the advantages of the treatment had a greater rate of response to treatment (p< 0.05).ConclusionPsychiatrists should routinely explore the patient conceptualization of the depression and to discuss together the best treatment approach. Prognosis, patient satisfaction and treatment response are significantly influenced by exploring the patient beliefs about its disorder.
P01-109 - Clinical-dynamic Characteristics of Depressive Disorders Comorbid with Anxiety Disorders
Authors: Vasilieva S.N. 
Published: June 2010

The aim of this study was to find clinical-dynamic characteristics of depressions comorbid with anxiety disorders.Methods140 patients have been observed: basic group - 70 patients with depressive disorder with anxiety disorder; control group - 70 patients with depressive disorder alone. All patients were treated with SSRIs. We used in study 17-item HRS-D and CGI.Results of investigationBaseline average score according to CGI has constituted 4,8±0,6 and 4,5±0,7. Comparative assessment of clinical picture of depression in groups has shown that in basic group more frequently (p< 0,05) dysphoric (31,4% and 12,9%) and conversion (21,4% and 11,4%) syndromes were noticed, while in the control group - adynamic (30% and 12,9%,). Statistical analysis of data of age at the onset of depressive disorder has revealed intergroup differences (p< 0,05), testifying to emerging depressive disorders in patients of basic group at younger age (39,6±12,1 years), as compared with patients of control group (43,9±12,9 years).Index of cyclicity of disease in patients with RDD was calculated as ratio of disease duration in years to cycles of disease. Average value of the corresponding index in basic and control groups differed reliably (p< 0,05) and has constituted 3,2±1,1 and 7,6±1,6. I.e., in the basic group exacerbation of depressive symptoms in recurrent depressive disorder was noticed more frequently as compared with control group.Thus, comorbidity of depressive and anxiety disorders results in complicating symptoms, change of its syndromal validation, more adverse course (acceleration of depressive phases in recurrent depressive disorder).
P01-12 - Gender Differences in Mental Distress among Heart Surgery Patients in Northern Norway
Authors: Bergvik S. , Wynn R. , Sørlie T. 
Published: June 2010

ObjectivesThere is a need for more research on women with coronary disease and potential gender differences. This paper report a study of gender differences in psychological distress, health behavior, and coronary health in patients having coronary artery bypass graft surgery (CABG).Methods229 patients (41 women) having CABG treatment at a hospital in Northern Norway completed a questionnaire 3-15 months after discharge (mean = 8.8, SD = 3.2), and medical data were gathered from their hospital records. Age ranged from 35 to 65 years (Mean = 60.5, SD= 7.4).ResultsNo gender differences were found on age, education, work status, or living alone, on coronary health measured by LVEF, NYHA, blood pressure, diabetes, on health related life style measured by smoking, BMI, and physical activity, or the number of days treated at the hospital, or time since hospital discharge.In univariate analysis, women (compared with men) reported higher levels of mental distress (SCL10; mean = 1.85 versus 1.57, t = 2.73, p< .006). Furthermore, women experienced the time at home following hospital discharge as more difficult than what men did. In a logistic regression analysis of gender, SCL10 together with LVEF were significant predictors, controlling for time since hospital discharge and days treated at the hospitalDiscussionThe higher rate of depression among female CABG patients in this study from Northern Norway is comparable to studies elsewhere. Results are discussed in light of theories of coping and self-regulation, other studies on gender differences in CAD, and implications for treatment.